The past year has been a turbulent one for Hikma. A shortage-fuelled growth spurt and a resulting guidance upgrade had heralded the Jordanian company’s entry into the FTSE 100 in March 2015 (following the c.25% rally since the beginning of the year), making it only the fourth pharma constituent to become a component of this ‘blue-chip’ index. Fast forward a year, however, and multiple downgrades later, investor enthusiasm towards the company had waned, resulting in the stock
21 Jun 2016
Reclaiming its FTSE 100 perch
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Reclaiming its FTSE 100 perch
Hikma Pharmaceuticals Plc (HIK:LON) | 1,926 0 0.0% | Mkt Cap: 4,274m
- Published:
21 Jun 2016 -
Author:
Jyoti Prakash -
Pages:
3
The past year has been a turbulent one for Hikma. A shortage-fuelled growth spurt and a resulting guidance upgrade had heralded the Jordanian company’s entry into the FTSE 100 in March 2015 (following the c.25% rally since the beginning of the year), making it only the fourth pharma constituent to become a component of this ‘blue-chip’ index. Fast forward a year, however, and multiple downgrades later, investor enthusiasm towards the company had waned, resulting in the stock